XML 57 R36.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($) $ in Millions |  |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | ---
Jul. 01, 2022 | Jun. 30, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |
One-time payment |  |  | $ (56.9) |  |  |  |  |
Revenues |  |  | 2,936.2 |  |  | $ 3,452.8 | $ 8,758.5 | $ 11,120.0
Sanofi Collaboration Agreement, Antibody |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |
Percentage share of profits to reimburse collaborating party |  |  |  |  | 10.00% |  |  |
Percentage of share of profits used to reimburse collaborating party for trial costs | 20.00% | 10.00% |  |  |  |  |  |
Revenue, remaining performance obligation, variable consideration amount |  |  | 100.0 |  |  |  | 100.0 |
Sanofi Collaboration Agreement, Antibody | Sales Milestone Three |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |
Revenues |  |  |  | $ 50.0 |  |  |  |
Levels of twelve-month sales at which sales milestone payments would be received |  |  |  | $ 2,000.0 |  |  |  |
Period for achieving sales target for milestone payment, rolling basis |  |  |  | 12 months |  |  |  |
Sanofi Collaboration Agreement, Antibody | Sales Milestone Four |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |
Levels of twelve-month sales at which sales milestone payments would be received |  |  |  |  |  |  | $ 2,500.0 |
Period for achieving sales target for milestone payment, rolling basis |  |  |  |  |  |  | 12 months |
Revenue, remaining performance obligation, variable consideration amount |  |  | $ 50.0 |  |  |  | $ 50.0 |
Sanofi Collaboration Agreement, Antibody | Sales Milestone Two |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  | 50.0 |  |
Levels of twelve-month sales at which sales milestone payments would be received |  |  |  |  |  | $ 1,500.0 |  |
Period for achieving sales target for milestone payment, rolling basis |  |  |  |  |  |  | 12 months |
Sanofi Collaboration Agreement, Antibody | Minimum |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |
Percentage of trial costs required to be funded by collaborating party |  |  |  |  |  |  | 80.00% |
Percentage share of profits to reimburse collaborating party |  |  |  |  |  |  | 30.00% |
Sanofi Collaboration Agreement, Antibody | Maximum |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |
Percentage of trial costs required to be funded by collaborating party |  |  |  |  |  |  | 100.00% |
Percentage share of profits to reimburse collaborating party |  |  |  |  |  |  | 50.00% |

X
- Definition Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received + References No definition available. + Details
Name: | regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment To Collaborating Party + References No definition available. + Details
Name: | regn_PaymentToCollaboratingParty
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs + References No definition available. + Details
Name: | regn_PercentageOfQuarterlyProfitsRequiredToBePaidForReimbursementOfDevelopmentCosts
Namespace Prefix: | regn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs + References No definition available. + Details
Name: | regn_PercentageOfShareOfProfitsUsedToReimburseCollaboratingPartyForTrialCosts
Namespace Prefix: | regn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of Trial Costs Required To Be Funded By Collaborating Party + References No definition available. + Details
Name: | regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
Namespace Prefix: | regn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period for Achieving Sales Target for Milestone Payment, Rolling Basis + References No definition available. + Details
Name: | regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
Namespace Prefix: | regn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount + References No definition available. + Details
Name: | regn_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_SalesMilestonesAxis=regn_SalesMilestoneThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_SalesMilestonesAxis=regn_SalesMilestoneFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | regn_SalesMilestonesAxis=regn_SalesMilestoneTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |